

# We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

## 4,800

Open access books available

## 122,000

International authors and editors

## 135M

Downloads

Our authors are among the

## 154

Countries delivered to

## TOP 1%

most cited scientists

## 12.2%

Contributors from top 500 universities

**WEB OF SCIENCE™**Selection of our books indexed in the Book Citation Index  
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?  
Contact [book.department@intechopen.com](mailto:book.department@intechopen.com)

Numbers displayed above are based on latest data collected.

For more information visit [www.intechopen.com](http://www.intechopen.com)

# Nutritional Treatment of Diabetic Foot Ulcers - A Key to Success

Patrizio Tatti<sup>1</sup> and Annabel Barber<sup>2</sup>

<sup>1</sup>*Diabetes and Endocrinology Unit – ASL RMH Roma*

<sup>2</sup>*University of Nevada, LV*

<sup>1</sup>*Italy*

<sup>2</sup>*USA*

## 1. Introduction

Diabetic Foot Ulcers (DFUs) represent a frequent occurrence in the diabetic population and up to 15% of these subjects may be expected to develop a foot ulcer at least one time in his/her life<sup>1,2</sup>. DFUs cause personal, social and economic problems and are a serious risk factor for death<sup>3,4</sup>. These ulcers can be broadly classified as neuropathic, vascular<sup>5</sup> or mixed, although the pathogenesis is much more complex. Biochemical<sup>6</sup>, hygienic<sup>7</sup>, structural deformity<sup>8,9</sup>, dynamic, pressure, skeletal, nutritional, socioeconomic factors, reduced antibacterial activity<sup>10,11,12</sup>, workplace influences, all concur to cause and maintain the lesion. A multicenter study attributed 63 percent of diabetic foot ulcers to the critical triad of peripheral sensory neuropathy, trauma, and deformity<sup>13</sup>. Most often healing requires the cooperation of many specialists, including surgeons, podiatrists, wound nurses and endocrinologists. In many cases, the definitive treatment demands minor or major surgery.

While the treatment of vascular ulcers is straightforward and requires a bypass or a radiologic procedure if the damage to the limb is to be limited or cured, the treatment of neuropathic ulcers is much more complex. Most often relief of the abnormal pressure does not lead to the healing of the ulcer, rather these wounds are characteristically chronic, with alternating periods of partial improvement and relapse. Sometimes a superimposing infection worsens the clinical condition. These ulcers in general do not lead to major amputation of the limb but frequently cause considerable economic, social and psychological burden on the patient and his relatives.

## 2. Etiology of the ulcer

The distinctive characteristic of the diabetic ulcer is the tendency to become chronic. There are many definitions of “chronic”. The American Heritage Medical Dictionary and Stedman’s Medical Dictionary define chronic ulcers as a “longstanding ulcer with fibrous scar at its base. A thorough search through the literature does not give an exact definition of this term. Sometimes one can read of “ulcers lasting more than six months” but this ignores the wide array of biological backgrounds and the phenotypic presentations of these ulcers. We propose an equally subjective but more realistic definition: “*an ulcer lasting more than one*

*could expect on the basis of previous experience in nondiabetic subjects*". The characteristic chronicity of the DFU was one of the bases for the diagnosis of diabetes before the introduction of the blood glucose assay. This idea penetrated the lore, and it is still possible to hear sentences like "I do not have diabetes, my ulcers heal quickly".

Chronic neuropathic ulcers usually occur as a result of a repeated trauma in the most exposed areas of the foot and ankle. However, not infrequently, may be the result of an acute trauma that is not recognized at the time of injury due to the relative pain insensitivity. The acute pathologic process is probably different and the outcome more favorable in the acute events versus the chronic ones.

The neuropathic ulcers have many concurrent factors that come into play to initiate and sustain the ulcer process. Among the risk factors, the presence of peripheral neuropathy with the consequent reduced or absent pain sensation, of bone deformity that exposes the bone heads to an abnormal load, and of trauma are prevalent<sup>13</sup>. Some form of diabetic neuropathy is present in nearly 65 % of diabetic patients. Fifty percent of these have a peripheral<sup>14</sup> that causes the loss of protective sensation. The often associated autonomic nerve dysfunction decreases sweating and causes thin, dry, fissured skin<sup>15,16</sup> that breaks easily. This autonomic dysfunction is one of the main causes of the severely damaged "Charcot foot"<sup>17,18</sup>. Trauma of any kind almost always has an initiating role. Acute wounds often are inadvertently self-inflicted during nail care or minor inadvertent injuries. Due to concomitant nerve damage, patients may not recognize or remember the trauma. The use of heaters to warm the feet or of overheated water to wash may cause burns or blisters that later develop into chronic wounds. The initiating factor in chronic pressure wounds most often is the repeated impact of an ill-fitting shoe on one area of the foot. Furthermore, diabetic patients have a peculiar rigidity of the joints that do not allow the foot to mold to the shoe or the floor<sup>19</sup>, thus creating an abnormal pressure and increasing the risk of injury. In many instances, calluses are an independent cause of injury, and is not uncommon to discover an ulcer beneath a callus.

Diabetic neuropathies appear with such wide array of different clinical presentations and in so many different places, sometimes symmetrically, less frequently as mononeuropathies, that finding a common cause has till now been impossible.<sup>20,21</sup> The most obvious culprit is hyperglycemia<sup>22</sup>, and at least at the beginning of the disease the normalization of the blood glucose can frequently revert to normal symptoms and signs of neuropathy.<sup>23,24</sup> Chronic hyperglycemia plays an important role in the appearance of neuropathy. It is well known from the Diabetes Control and Complication Trial (DCCT) that strict control of blood glucose in newly diagnosed non complicated type 1 diabetics decreases the development of peripheral neuropathy in 60% of the cases over 5 years <sup>25,26</sup>. However, the exclusive role of hyperglycemia has been challenged on the basis of the failure in some cases to achieve improvement of neuropathy with blood glucose control<sup>27,28</sup> and other observations among which the increased incidence of this condition in prediabetes, <sup>29,30,31</sup> a state in which the blood glucose is still normal. Alternatively, a role of insulinopenia has been suggested.<sup>32,33</sup> Insulin receptors are present in the peripheral nervous system, and it is conceivable that any malfunction of insulin delivery<sup>34</sup> may damage the function of neurons. There is also proof that in an experimental model of diabetes, a modest reduction of insulin levels even without an increase of the blood glucose levels can reduce the pain threshold.<sup>35,36</sup> Thus it is possible that the insulin level required to regulate the nerve function is higher than that needed for

glucose control. Further, neuropathy can appear early also in type 2 diabetes<sup>37,38</sup> where at least in the prediabetic stages, there is a compensatory hyperinsulinemia coupled with an increase in insulin resistance. This and the previous observation that a higher level of insulinemia is probably required for the regulation of the nervous than the glycemic system may point to a role of insulin resistance. In this case, the compensatory hyperinsulinemia could be present for many years and be effective to prevent the occurrence of overt diabetes, but not to prevent the nerve damage. Or, in turn, the insulin resistance could involve the nervous receptors to a higher degree than those involved in glucoregulation. It has also been shown that Insulin Growth Factor 1 (IGF1), a molecule that mimics many insulin effects,<sup>39,40,41</sup> induces recovery of the nerve function in rats<sup>42</sup>. Taken together, these hypotheses fail to explain the pathogenesis of diabetic peripheral neuropathy and do not confirm an exclusive role of hyperglycemia. On the other hand, there is no doubt that hyperglycemia causes the microvascular damage frequently associated with the DFU. In a recent study the Authors found a graded association between HbA1C and carotid Intima Media Thickness (IMT) that is currently considered the best marker of progression of atherosclerosis.<sup>43</sup> In this study LDL and HDL cholesterol, plasma triglycerides, and waist-to-hip ratio were significantly associated with HbA1c after multivariable adjustment. Among other factors interfering with healing at the cellular level, the prevalence of infections in diabetics should not be overlooked. Chemotaxis, phagocytosis and all the bactericidal actions of neutrophils are impaired in uncontrolled diabetes<sup>44,45</sup>. Also the formation of Advanced Glycation Endo Products (AGE), that can bind to specific receptors on the leucocyte membrane (RAGE), may further impair the leucocyte antibacterial activity.<sup>46</sup> Thus, at present we have not identified a distinctive cause nor we have a definite role for the co-causal factors. One hypothesis put forward to explain the appearance and/or the progression of diabetic neuropathy is that impairment of synthesis of proteins may be the primary insult leading to the centripetal necrosis of the neuron<sup>47,48,49,50,51</sup>. Because this aspect is strictly connected with the topic of nutrition we will deal with it later in this chapter. This and many other hypotheses and their support were recently discussed in depth<sup>52</sup> and are beyond the scope of his chapter

### 3. The body composition of the subjects with an ulcer

The body of a diabetic is different from the body of a person who has a normal blood glucose level. The well known changes at the molecular level, notably the accumulation of AGEs<sup>53</sup> cause in time morphological changes of the tissues, with diffuse damage to the vascular walls, reduction of the body cell mass and lean body mass<sup>54</sup>, skin stiffness and prevalence of fat.

What we broadly define lean body mass is in reality a composite of what is mostly the structural - protein component of the body including muscle, parenchymal organs, red blood cells, enzymes, mitochondria and the like,<sup>55</sup> and has a critical role in maintaining the integrity of the body and permitting the survival. Although surprising there are very few studies of the body composition of type 2 diabetic subjects. To fill this gap we compared the body composition of 244 subjects with type 2 diabetes mellitus and demonstrated a reduction in the Body Cell Mass index (an index of the % mass of cells normalized for the actual height of the subject) in both sexes versus 266 non diabetic matched controls. Furthermore in 715 diabetics we also demonstrated that this reduction was proportional to

both the prevailing level of HbA1c in the last year and the duration of disease, although with the multiple regression analysis the former appears to account for most of the actual reduction<sup>52</sup>.

There are many possible explanations for the protein/lean body mass loss: (1) the body of the diabetic is in a continuous catabolic state due to insulin deficiency and to the phenomenon of neoglucogenesis continuously turning aminoacids and fat into harmful glucose. This process lasts throughout the day in uncompensated diabetes<sup>56</sup> without interruption at mealtime and is proportional to the blood glucose level<sup>57</sup>, in accordance with our observations. (2) Most diabetics have a persistent microalbuminuria, which represents another source of protein loss<sup>58</sup> (3) the wound itself is a source of protein loss proportional to the size and depth of the lesion.<sup>59</sup> (4) Because of the concomitant kidney damage these patients are frequently put on a protein reduced diet, on unsupported grounds<sup>60</sup>, thus aggravating their protein depletion.

Furthermore the presence of the wound tends to change the metabolic environment towards catabolism: the secretion of proinflammatory cytokines in proportion to the size and the condition of the lesion increases the insulin resistance deranging glucose metabolism, and drives the body into a catabolic state. This phenomenon is particularly dangerous in diabetics who already have high circulating levels of cytokines secreted by the excess abdominal fat. The increased cortisol secretion as part of the stress response to the wound adds to the catabolism: less energy is derived from the fat mass, and the protein catabolism is increased. In turn the release of aminoacids drives the neoglucogenesis in the liver.

To add further to this catabolic state, diabetic subjects have reduced levels of most anabolic hormones. Beyond the obvious absence or ineffectiveness of insulin on protein metabolism<sup>61,62,63</sup> these subjects have a subnormal level of testosterone (low testosterone syndrome)<sup>64,65,66,67</sup> with a characteristic hypogonadotropic hypogonadism<sup>64</sup> responsible for the decreases the lean body mass. In view of all these events occurring together it is not surprising that most of these subjects are in a protein depleted state. As suggested before, it is possible that the failure of proteins synthesis involved in nerve functioning may result in impaired nerve regeneration and death.<sup>68,69,70,71</sup>

Loss	Catabolism	Reduced supply
Kidney (microalbuminuria)	Low testosterone	Diet
Liver (neoglucogenesis)	Low GH	Protein losing enteropathy
Ulcer (exudate)	Fat derived cytokines	diarrhea

Table 1. Common causes of protein malnutrition in the diabetic

It is thus clear that decompensated diabetes is a catabolic condition further aggravated by the stress reaction and this creates a conflict with the ancestral mechanisms of survival of the body. A better comprehension of the wound healing process can be acquired through an analysis of these processes. The human body is programmed for survival and has a hierarchy of priorities for this aim<sup>72</sup>. The primary need is the conservation of the lean body mass defined as above as a composite of muscle, circulating enzymes, red blood cells, all the parenchymal organs, the immune organ and the water representing the metabolic and structural machinery of the body. Stated more simply the lean body mass is

all that is not fat. Any reduction of this mass poses a risk to survival. This compartment is continuously refilled with the proteins derived from the diet. The average energy need of a healthy young 70 kg person is 2500 cal / die obtained from the diet. Usually 20% of these (125 gr) derive from protein. However in times of abundance, when the lean body mass is replete, the organism deals with the wound as a nutritional priority and any aminoacid and protein supply acquired through the diet are diverted to the wound to promote the closure<sup>73</sup>. This diversion to the skin is a damage to the lean body mass because subtracts the aminoacids from the diet in proportion to the size and the depth of the ulcer. If the lesion is exceedingly large and deep also the protein content of the lean body mass is catabolized to aminoacids to support the repair of the skin. When more than 15-20% <sup>74,75,76</sup> of the lean body mass is lost the survival mechanism changes radically its perspective and the true priority becomes the maintenance of this structure. Under these conditions the body uses all the hormonal and metabolic tools available to support the lean body mass, that includes antibodies and immune cells and almost nothing is left for the wound. The integrity of this lean mass is so critical that its reduction to  $\leq 60\%$  of the initial value usually leads to failure of the immune function and death due to pneumonitis<sup>77</sup>.




Fig. 1. Main causes of protein malnutrition in diabetes

We should envisage the body as a sophisticated system with a central compartment (Lean Body Mass, LBM) supplying the periphery on demand. If a peripheral lesion (the ulcer) supervenes the central compartment supplies protein until a danger level of depletion is reached. The human body does not have a reservoir of spare proteins, and these have a low energetic yield. Thus a critical level of depletion is reached soon. This phenomenon is even more prominent in the protein depleted diabetics. In these subjects the central compartment of LBM is frequently already in borderline-low conditions and subtracts all the alimentary supply of proteins. In these conditions an ulcer will never heal.

In summary, in the presence of a chronic ulcer in a longstanding diabetic subject, we must always assume the existence of a certain degree of lean body mass (LBM) loss. The Body Bioimpedance analysis (BIA) is a widely used method for estimating the body composition and the presence of this condition. The technology is relatively simple, quick and noninvasive and evaluates the electrical impedance of body tissues, which provides an estimate of total body water (TBW). This value can be used to calculate the fat-free mass (FFM) and body fat (adiposity). In addition this technology can be used to evaluate the body cell mass (BCM). When the BCM is corrected for the actual height of the subject (Body Cell Mass Index, BCMI) gives a very accurate estimate of the total cellular mass and is a useful tool to assess the nutritional state, more so if a previous report is available for comparison to estimate the degree of damage.<sup>78</sup>

Diabetic foot ulcers tend to occur in the advanced stages of the disease. The usual saying that a characteristic of early diabetes is the slow healing of wounds dates back to a period when the diagnosis of the disease was delayed. Today a diagnostic delay only occurs in the poor and the underprivileged. In these subjects the catabolic state is usually well advanced and the skin is thin with widespread loss of the subcutaneous tissue, and a chronic nonhealing ulcer can be a presenting sign of diabetes. We demonstrated in 700 diabetics that at this stage the loss of the lean body mass is already advanced, and that the use of re-feeding solutions containing an increased percentage of proteins can help to recreate the lean body mass<sup>52</sup> and the subcutaneous tissue<sup>79</sup>

Clinical scenario	Favorable	Intermediate	Worst
Wound: Size Caloric / protein requirement	-Small -low	-medium -intermediate	-large -high
Lean body mass	-healthy	Healthy/ slightly reduced	-markedly reduced
Nutrition	Sufficient	Sufficient/scant	Scant
Pathophysiology	External supply redirected in percentage towards the ulcer	External supply partitioned between the ulcer and the fat free mass	External supply redirected towards the lean body mass
Ulcer	Heals rapidly	Ulcer healing delayed /absent	No ulcer healing

#### Current treatments

Since a single cause of the nonhealing diabetic foot ulcer has not been identified a variety of different products acting on, mimicking, or purportedly having magic qualities, have been introduced on the market without substantial proof of benefit, and often lacking rationale.

Although frequently emphasized, the general condition of the patient, the strict control of his blood glucose and the general nutritional status are too frequently overlooked, mostly

in the general medical or surgical wards, where the attention is focused on the ulcer itself. The concern for the local factors and the commercial pressure of the pharmaceutical companies generated an incredible number of local treatments, including ointments, growth factors and the so called "advanced medications" containing a variety of metals and ions that should stimulate the reparative process. However the use of these substances did not demonstrate any substantial improvement in clinical studies. Although we do not think that these medications have a great role, we must acknowledge that proving the efficacy of these substances in healing ulcers with randomized controlled studies is a complicated and expensive task. It is evident that recruiting an adequate number of subjects with the same duration of disease, a similar degree of diabetic control, and an ulcer of the same characteristics for a randomized controlled trial is very difficult, and unless a substance has truly magical properties the statistical results will be open to discussion<sup>80,81,82</sup>

What starts the cascade of problems in the diabetic is an alteration of glucose metabolism that in turn causes a series of metabolic derangements, and the dire consequences that follow. In a recent study the Authors found a significant prevalence of HbA1c  $\geq 7\%$  (53 mmol/mol) and HDL  $\leq 50$  mg/dl in diabetic subjects with lower extremity disease versus those without.<sup>83</sup> But if things are so simple, why is the normalization of blood glucose alone not able to induce tissue regrowth and ulcer healing? The answer is that a diabetic foot ulcer only appears after a long period of decompensated diabetes, when the nerves, the skin and all the supporting tissues and structures are already severely damaged or impaired and the simple correction of the causal abnormality is not enough. In this respect is worthwhile to mention the results of the Accord study casting doubt on the feasibility of intensive blood glucose control in diabetic patients with complications. In this study after an average of 3.5 years, 257 people in the intensive blood glucose lowering strategy group died, compared to 203 participants in the standard strategy group. This difference of 54 deaths resulted in a 22 percent increased death rate in the intensive group. Since the presence of a DFU is a complication these results have an important bearing on the treatment of these subjects.<sup>84</sup>

Under normal circumstances the healing of an ulcer requires energy supplied by lipids and glucose. The role of glucose is probably the most complex because this molecule is part of the structural glycoproteins, of some enzymes<sup>85,86</sup> and fuels the inflammatory cells<sup>87</sup>. Lipids for the energetic needs of healing can be obtained from the diet or from fat deposits. As happens for glucose, lipids have multiple functions: the most well known is energy storage, but these molecules also have signaling capacity and are structural components of the cell membrane. Both glucose and lipids must be available for the normal healing processes of the ulcers, but diabetics have a characteristic difficulty disposing of glucose inside the cells that can be only partially reversed with the available treatments. Proteins are structural components of the skin, but these subjects almost always have a degree of preexistent protein deficiency that must be taken into account when planning a diet. Estimating the degree of deficiency is the difficult part because the body composition is an individual characteristic and no "normal values" exist. The available tools to evaluate the degree of LBM and indirectly the degree of protein loss, like Bioimpedance Analysis and Skin Fold Thickness, are only useful in the presence of



previous records of the same subject. The body weight loss, another simple and sequentially available measurement does not give any information on the body compartments and is thus of limited utility. However the presence of a nonhealing ulcer implies the loss of at least 20% of the LBM. When estimating the calorie-protein need of a diabetic the most reasonable option is to err on the excessive side.

Although the role of nutrition is crucial and usually acknowledged, it is surprising how often is overlooked in practice. The most recent edition of the ADA book on the treatment of DFU<sup>88</sup> does not even mention the general condition and the nutritional status of the patient among the aspects to evaluate.

Our hypothesis is that the damage to the tissues is both preventable and at least partially reversible if the treatment is directed towards all the main causal factors. In other words, in our opinion if the vascular blood supply is normalized, the blood glucose level is kept under control, the abnormal pressure is reduced with adequate biophysical support and the texture of the skin is reconstituted there is absolutely no place for growth factors, colloids, metals or whatever else. The diabetic now has the same ability to heal as nondiabetics. The reconstitution of the skin requires the supply of proteins and other biological material that is usually reduced in the diabetic and must be supplied with adequate nutrition. The avoidance of relapses requires attention to postural and neurologic factors.

#### 4. Treatment

The role of the nutritional condition of the patient with a DFU is crucial to the pathogenesis and treatment of the lesion, but infrequently recognized or treated. Accordingly, we think that the term "treatment of the DFU" is a misnomer and should be substituted with "treatment of the subject with a DFU". We suggest a series of steps<sup>89</sup>:

1. Whenever possible the nutritional condition should be assessed as accurately as possible, with Bio-Impedance Analysis, Skin Fold Thickness, Body Weight and Blood chemistry studies (protein electrophoresis, BUN, Hemogram). If previous values are available the change should be included as part of this assessment.
2. The resting caloric requirement should be calculated as 20-25 kcal/kg body weight. This value decreases in the elderly. The value so obtained should be multiplied by 1.2-1.5 according to the severity of the lesion.<sup>90</sup> This figure should be increased if there is evidence of malnutrition.
3. Add the caloric expenditure of activity. All these measurements can be obtained with the use of indirect calorimetry or with the recently introduced non-invasive tools worn at the arm that are worn over a longer period of time. The statistical elaboration of the Bio-Impedance Analysis can yield a reliable estimate of the Basal Metabolic Rate
4. The value so obtained should be multiplied by a "stress factor" that varies from 1.2 for clean wounds, to 1.5 in the case of infected wounds

All these calories should be replaced with an adequate diet, with no less than 20-22% protein given in at least three divided doses throughout the day. These values should be increased by 30-50% according to the co-morbidities of the subject. Paddon Jones suggests that non diabetic elders should have a minimum of 15 g of essential amino acids, equivalent to about

30 g of high-quality dietary protein at each meal.<sup>91</sup> Although there are no fast and hard rules this figure must be increased in the diabetic with a chronic wound.

Another critical component is hydration<sup>92</sup>. We suggest to drink at least 2-3 lt of water per day. In addition to the maintenance of the circulation and the tissue exchange of metabolites, the water induced diuresis helps the body to get rid of the excess glucose.

Some trace substances and vitamins are also absolutely needed for the healing process. In particular Vitamin C, E, Selenium and  $\beta$ -carotene with strong antioxidant properties that antagonize the harmful oxygen free radicals (ROS) present in excess in the chronic wound<sup>93</sup>. Vitamin C is also needed for collagen formation.<sup>94</sup>

The progression of the ulcer should be evaluated with inspection, with photographic records including a ruler close to the lesion, with the biochemical analytes useful to monitor the inflammation and the nutritional state (ESR, Hemogram, CRP, Albumin and Prealbumin levels), and the BIA.

## 5. The role of supplements

The body of the diabetic is in a general catabolic state and restituting the normal catabolism is a distinctive advantage for the treatment. According to this principle testosterone treatment has been instituted.<sup>95</sup> We use transdermal testosterone supplement in testosterone deficient subjects with apparent reduction in healing time, although we did not conduct a systematic study. Other anabolic hormones have been used with variable results.<sup>96</sup> We have a good experience with an oral nutritional supplement, a blend containing Argine, glutamine and  $\beta$ -hydroxy- $\beta$ -methyl-butyrate (HMB). HMB is normally present in the muscle, is an active leucine metabolite and a potent stimulator of mTOR (Mammalian Target of Rapamycin), an intracellular protein controlling protein synthesis.<sup>97,98</sup> Due to this anabolic property, the substance is widely used by the athletes worldwide, and to reverse the effects of aging.<sup>99</sup> Glutamine also has a spectrum of positive effects<sup>100</sup>, notably stimulation of protein synthesis and support of immune function.<sup>101,102</sup> and a positive effect on intestinal integrity.<sup>103</sup> Its effectiveness in collagen formation has also been consistently proven.<sup>104</sup> Arginine also has a positive effect on wound healing<sup>105</sup>, and stimulates immune function.<sup>106,107</sup> Arginine also has a vasodilator action<sup>108</sup> that was exploited for male erectile dysfunction before the introduction of the phosphodiesterase inhibitors. In our experience the use of this blend reduced to 1/3 the time to healing in a group of 12 diabetic patients while improving the lean body mass.<sup>109</sup> We also found an unexpected reduction of microalbuminuria in 16 diabetic subjects under treatment with this blend, which might concur to explain the increase in lean body cell mass<sup>110</sup>

It should be emphasized that the use of anabolic substances or blends is no substitute for an adequate nutrition with enough protein, calories, minerals, vitamins and iron that can be found in the normal Western diet. Therefore, the best nutritional approach to the diabetic patient is: (1) the evaluation of the degree of wasting of the lean body mass and of the degree of current needs; (2) institution of a diet supplying what is missing and what is currently required, supplemented with enough protein, and distributed in at least three meals per day. This diet should be integrated with vitamins, minerals and iron; (3) use of

anabolic agents or a blend of the three substances we used. Irrespective of which medical treatment will be used, the closure of a wound will be impossible unless these steps are followed.

## 6. References

- [1] McNeely MJ, et Al: The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration. *Diabetes Care* 18:216-219, 1995
- [2] National Diabetes Data Group: *Diabetes in America*. Vol. 2. Bethesda, MD, National Institutes of Health, 1995 (NIH publ. no.95-1468)
- [3] Van Baal J, MSC et Al. Mortality Associated With Acute Charcot Foot and Neuropathic Foot Ulceration. *Diabetes Care* 33:1086-1089, 2010
- [4] Leese GP, et Al A: Predicting foot ulceration in diabetes: validation of a clinical tool in a population-based study. *Int J Clin Prac* 60:541-545, 2006
- [5] Tan PL, Teh J. MRI of the diabetic foot: differentiation of infection from neuropathic change. *Br J Radiol. Nov 2007;80(959):939-48.*
- [6] Christian Weigelt, MD et Al. Immune Mediators in Patients With Acute Diabetic Foot Syndrome. *Diabetes Care* 32(2009):1491-1496,
- [7] Calle-Pascual A. et Al, Reduction in Foot Ulcer Incidence (letter). *Diabetes Care, Volume 24, N 2, (2001):405-7*
- [8] Van Schie C. H.M., PHD et Al. Muscle Weakness and Foot Deformities in Diabetes. *Diabetes Care, Vol 27, N 7, (2004):1668-73*
- [9] Sicco A. Intrinsic Muscle Atrophy and Toe Deformity in the Diabetic Neuropathic Foot. *Diabetes Care* 25 (2002):1444-1450
- [10] Boulton AJ, Vileikyte L: The diabetic foot: the scope of the problem. *J Fam Pract* 49 (Suppl. 11):S3-S8, 2000
- [11] Levin M: Pathophysiology of diabetic foot lesions. In *Clinical Diabetes Mellitus: A Problem-Oriented Approach*. Davidson JK, Ed. New York, Theme Medical, 1991, p. 504-510
- [12] Lawrence A. L . et Al Risk Factors for Foot Infections in Individuals With Diabetes. *Diabetes Care* 29 (2002):1288 -1293
- [13] Reiber GE et Al Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. *Diabetes Care*.1999;22:157-62.
- [14] Vinik A. et Al. Diabetic Autonomic neuropathy. *Diabetes Care, Vol 26, N 5, (2003):1553-79*
- [15] Vinik, AI. Et Al. Diabetic neuropathies: an overview of clinical aspects. In: LeRoith, D.; Taylor, SI.; Olefsky, JM., editors. *Diabetes Mellitus*. Philadelphia, New-York: Lippincott-Raven Publishers; 1996. p. 737-751.
- [16] Boulton AJM. The diabetic foot: from art to science. The 18th Camillo Golgi lecture. *Diabetologia* (2004);47:1343-1353
- [17] Armstrong DG, et Al. The natural history of acute Charcot's arthropathy in a diabetic foot specialty clinic. *Diabet Med* (1997);14:357-63
- [18] Brower AC, Allman RM. The neuropathic joint: a neurovascular bone disorder. *Radiol Clin North Am* (1981);19:571-80

- [19] Zimm S et Al. The Role of Limited Joint Mobility in Diabetic Patients With an At-Risk Foot. *Diabetes Care* 27(2004):942–946
- [20] Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetics. *Muscle Nerve* (1988);11:21–32. [PubMed: 3277049]
- [21] Boulton AJ, et Al. Diabetic neuropathies: a statement by the American Diabetes Association. *Diabetes Care* (2005);28:956–962. [PubMed: 15793206]
- [22] Adler AI et Al. Association between glycated haemoglobin and the risk of lower extremity amputation in patients with diabetes mellitus – review and meta-analysis. *Diabetologia* (2010) 53:840–849
- [23] Thomas PK. Diabetic neuropathy: mechanisms and future treatment options. *J Neurol Neurosurg Psychiatry* (1999);67:277–279. [PubMed: 10449543]
- [24] Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. *Diabetes* (1997);46 (Suppl 2):S54–S57. [PubMed: 9285500]
- [25] Lasker RD. The diabetes control and complications trial. Implications for policy and practice. *NE J Med* (1993);329:1035–1036. [PubMed: 8366905]
- [26] The Diabetes Control and Complications Trial Research Group (DCCT). The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. *N Engl J Med* (1993);329:977–986. [PubMed: 8366922]
- [27] Sugimoto K, Murakawa Y, Sima AA. Diabetic neuropathy--a continuing enigma. *Diabetes Metab Res Rev* (2000);16:408–433. [PubMed: 11114101]
- [28] Young RJ et Al. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. *Diabetes* (1983);32:938–942. [PubMed: 6225686]
- [29] Argoff CE, et Al. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. *Mayo Clin Proc* (2006);81:S3–11. [PubMed: 16608048]
- [30] Singleton JR, et Al. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. *Diabetes Care* (2001);24:1448–1453. [PubMed: 11473085]
- [31] Novella SP, et Al. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. *Muscle Nerve* (2001);24:1229–1231. [PubMed: 11494278]
- [32] Brussee V, et Al. Direct insulin signaling of neurons reverses diabetic neuropathy. *Diabetes* (2004);53:1824–1830. [PubMed: 15220207]
- [33] Huang TJ, et Al. Insulin prevents depolarization of the mitochondrial inner membrane in sensory neurons of type 1 diabetic rats in the presence of sustained hyperglycemia. *Diabetes* (2003);52:2129–2136. [PubMed: 12882932]
- [34] Sugimoto K, et Al. Insulin receptor in rat peripheral nerve: its localization and alternatively spliced isoforms. *Diabetes Metab Res Rev* (2000);16:354–363. [PubMed: 11025559]
- [35] Singhal A et Al. Near nerve local insulin prevents conduction slowing in experimental diabetes. *Brain Res* (1997);763:209–214. [PubMed: 9296561]
- [36] Brussee V, et Al. Direct insulin signaling of neurons reverses diabetic neuropathy. *Diabetes* (2004);53:1824–1830. [PubMed: 15220207]

- [37] Singleton JR, et Al . Polyneuropathy with Impaired Glucose Tolerance: Implications for Diagnosis and Therapy. *Curr Treat Options Neurol* (2005);7:33–42. [PubMed: 15610705]
- [38] Russell JW, Feldman EL. Impaired glucose tolerance--does it cause neuropathy? *Muscle Nerve* (2001);24:1109–1112. [PubMed: 11494263]
- [39] Frasca F, et Al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. *Mol Cell Biol* (1999);19:3278–3288. [PubMed: 10207053]
- [40] Rajkumar K, et Al. Impaired glucose homeostasis in insulin-like growth factor binding protein-1 transgenic mice. *J Clin Invest* (1996);98:1818–1825. [PubMed: 8878433]
- [41] Meier C, et Al . Developing Schwann cells acquire the ability to survive without axons by establishing an autocrine circuit involving insulin-like growth factor, neurotrophin-3, and platelet-derived growth factor-BB. *J Neurosci* (1999);19:3847–3859. [PubMed: 10234017]
- [42] Zhuang HX et Al. Insulin-like growth factor (IGF) gene expression is reduced in neural tissues and liver from rats with non-insulin-dependent diabetes mellitus, and IGF treatment ameliorates diabetic neuropathy. *J Pharmacol Exp Ther* (1997);283:366–374. [PubMed: 9336345]
- [43] Selvin E et Al. Glycemic control, atherosclerosis and risk factors for cardiovascular disease in individuals with diabetes. *Diabetes Care* 28:1965–1973, 2005
- [44] Delamaire, M et Al. Impaired leucocyte functions in diabetic patients *Diabet. Med.* (1997), 14, 29-34
- [45] Davidson, N.J. et Al Defective phagocytosis in insulin controlled diabetics: evidence for a reaction between glucose and opsonising proteins. *J. Clin. Pathol.*, (1984),37, 783-6.
- [46] Collison, K.S et Al. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs), *J. Leukoc. Biol.* (2002), 71, 433-44
- [47] Thomas PK. Diabetic neuropathy: mechanisms and future treatment options. *J Neurol Neurosurg Psychiatry* (1999);67:277–279. [PubMed: 10449543]
- [48] Zochodne DW. Neurotrophins and other growth factors in diabetic neuropathy. *Semin Neurol* (1996);16:153–161. [PubMed: 8987129]
- [49] Britland ST et Al. Association of painful and painless diabetic polyneuropathy with different patterns of nerve fiber degeneration and regeneration. *Diabetes* (1990);39:898–908. [PubMed: 2373262]
- [50] Sima AA. Peripheral neuropathy in the spontaneously diabetic BB-Wistar-rat. *An ultrastructural study. Acta Neuropathol (Berl)* (1980);51:223–227. [PubMed: 7445976]
- [51] Liuzzi FJ, Bufton SM, Vinik AI. Streptozotocin-induced diabetes mellitus causes changes in primary sensory neuronal cytoskeletal mRNA levels that mimic those caused by axotomy. *Exp Neurol* (1998);154:381–388. [PubMed: 9878176]
- [52] Dobretsov M et Al. Early diabetic neuropathy: Triggers and mechanisms. *World J Gastroenterol.* (2007) January 14; 13(2): 175–191.
- [53] Peppia M et Al. Glucose, Advanced Glycation End Products, and Diabetes Complications: What Is New and What Works. *Clinical Diabetes, Volume 21, Number 4,* (2003):186-7


- [54] Tatti P et Al. Reduced body cell mass in type 2 diabetes mellitus: reversal with a diabetes specific nutritional Formula. *Mediterr J Nutr Metab* (2010) 3:133–136
- [55] *Webster's Medical Dictionary*
- [56] Monnier L, Colette C. Contributions of fasting and postprandial glucose to hemoglobin A1c. *Endocr Pract* (2006) Jan-Feb;12 Suppl 1:42-6
- [57] DeFronzo RA, Banting Lecture. *Diabetes*, Vol. 58, April 2009:773-95
- [58] Guerrero-Romero F, Rodriguez-Mòran M. Relationship of microalbuminuria with the diabetic foot ulcers in type II diabetes. *J Diabetes Complications*, (1998) Jul-Aug;12(4):193-6.
- [59] M. Lehnhardt et Al. A qualitative and quantitative analysis of protein loss in human burn wounds. *Burns Vol 31, issue 2, (March 2005); 159-67*
- [60] Koya D et Al. Long term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomized controlled trial. *Diabetologia* (2009)52:2037-45
- [61] Biolo G, et Al. Physiological hyperinsulinemia stimulates protein synthesis and enhances transport of selected amino acids in human skeletal muscle. *J Clin Invest* 95 (1995): 811–819
- [62] Fryburg DA, et Al. Insulin and insulin-like growth factor-1 enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms. *J Clin Invest* 96 (1995): 1722–1729,.
- [63] Møller-Loswick AC, et Al. Insulin selectively attenuates breakdown of nonmyofibrillar proteins in peripheral tissues of normal men. *Am J Physiol Endocrinol Metab* 266 (1994): E645–E652,.
- [64] Grossmann M, et Al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. *J Clin Endocrinol Metab* 93 (2008):1834-40.
- [65] Sandeep Dhindsa, et Al. Testosterone Concentrations in Diabetic and Nondiabetic Obese Men. *Diabetes Care* 33 (2010):1186–1192,
- [66] Dhindsa S, et Al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. *J Clin Endocrinol Metab* (2004);89:5462–5468
- [67] Dhindsa S, et Al. The effects of hypogonadism on body composition and bone mineral density in type 2 diabetic patients. *Diabetes Care* (2007);30:1860–1861
- [68] Zochodne DW. Neurotrophins and other growth factors in diabetic neuropathy. *Semin Neurol* (1996);16:153–161. [PubMed: 8987129]
- [69] Britland ST et Al. Association of painful and painless diabetic polyneuropathy with different patterns of nerve fiber degeneration and regeneration. *Diabetes* 39 (1990);898–908. [PubMed: 2373262]
- [70] Sima AA. Peripheral neuropathy in the spontaneously diabetic BB-Wistar-rat. An ultrastructural study. *Acta Neuropathol (Berl)* (1980);51:223–227. [PubMed: 7445976]
- [71] Liuzzi FJ, et Al. Streptozotocin-induced diabetes mellitus causes changes in primary sensory neuronal cytoskeletal mRNA levels that mimic those caused by axotomy. *Exp Neurol* (1998);154:381–388. [PubMed: 9878176]

- [72] Moore FD, Brennan M. Surgical injury, body composition, protein metabolism and neuron-endocrinology. In: *Ballinger W, Collins J, eds. Manual of Surgical Nutrition. Philadelphia, Pa: W. B. Saunders; (1975);169–202.*
- [73] Wernerman J, et Al. The effect of stress hormones on the interorgan flux of amino acids and concentration of free amino acids in skeletal muscle. *Clin Nutr. (1985);4:207–16*
- [74] Say J. The metabolic changes associated with trauma and sepsis [review]. *Nurs Crit Care. (1997);2:83–7.*
- [75] Chioliro R, et Al. Energy metabolism in sepsis and injury [review]. *Nutrition. (1997);13, suppl 9:45S–51S.*
- [76] Cartwright M. The metabolic response to stress: a case of complex nutrition support management [review]. *Crit Care Nurs Clin North Am. (2004);16:467–87.*
- [77] Moran L, et Al. Nutritional assessment of lean body mass. *J Pen. (1980);4:595.*
- [78] A. Talluri. The application of body cell mass index for studying muscle mass changes in health and disease conditions. *Acta Diabetologica. Volume 40, Supplement 1, s286-s289, DOI: 10.1007/s00592-003-0088-9*
- [79] Tatti P et Al. Extremely accelerated healing of diabetic foot ulcers with medical nutrition therapy: *Int J Diabetes & Metabolism (2009) 17:115-116*
- [80] Ritu Jones et Al. The external validity of published randomized controlled trials in primary care *BMC Family Practice (2009), 10:5 doi:10.1186/1471-2296-10-5*
- [81] Tones K. Evaluating health promotion—beyond the RCT. In: *Norheim L, Waller M, eds. Best Practices, Quality and Effectiveness of Health Promotion. Helsinki, Finland: Finnish Centre for Health Promotion; 2000: 86–101*
- [82] Sibbald B, Roland M. Understanding controlled trials: Why are randomised controlled trials important? *BMJ 316 : 201 (Published 17 January 1998)*
- [83] Dorsey RR, et Al. Control of risk factors among people with diagnosed diabetes, by lower extremity disease status. *Prev Chronic Dis 2009;6(4).* [http://www.cdc.gov/pcd/issues/2009/oct/08\\_0224.htm](http://www.cdc.gov/pcd/issues/2009/oct/08_0224.htm)
- [84] The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. *N Engl J Med 2008; 358:2545-2559 June 12, 2008*
- [85] Irelton-Jones C, Liepa R. Carbohydrates and wound healing in nutrition. In: *Molner J, ed. Nutrition and Wound Healing. Boca Raton, Fla: CRC press; (2006):5.*
- [86] Patel G. The role of nutrition in managing lower extremity wounds. *Int J Low Extrem Wounds. (2005);4:12–22*
- [87] Hart D, Wolf S, Zhang X, et al. Efficacy of a high energy carbohydrate diet in catabolic illness. *Crit Care Med. (2001);29:1318*
- [88] American Diabetes Association. *Clinical Care of the diabetic Foot, 2nd Edition (2010)*
- [89] Demling RH. Nutrition, Anabolism, and the Wound Healing Process: *An Overview. ePlasty, published Feb 3, Vol 9(2009):65-94*
- [90] Dorner B et al. The role of nutrition in pressure ulcer prevention and treatment: National Pressure Ulcer Advisory Panel White Paper. *Adv Skin Wound Care 2009;22:212-221.*

- [91] Paddon-Jones D et al. Dietary protein recommendations and the prevention of sarcopenia. *Curr Opin Clin Nutr Metabolic Care* 2009;12:86-90.
- [92] Institute of Medicine. National Academy of Sciences: Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate. Washington, DC, 2004. [Http://www.iom.edu/?id=54343](http://www.iom.edu/?id=54343) "http://www.iom.edu/?id=54343
- [93] Clark RAF. Oxidative stress and "senescent" fibroblasts in nonhealing wounds as potential therapeutic targets. *J Invest Dermatol* (2008);128:2361-2364.
- [94] Morris SM. Recent advances in arginine metabolism: roles and regulation of the arginases. *Br J Pharmacol* (2009);157:922-930
- [95] Demling R, DeSanti L. The anabolic steroid oxandrolone reverses the wound healing impairment in corticosteroid dependent burn and wound patients. *Wounds*. (2001):203-8.
- [96] Lang C, Frost R. Role of growth hormone, insulin-like growth factor-1 and insulin-like growth factor binding proteins in the catabolic response to injury and infection. *Curr Opin Clin Nutr Metab Care*. 2002:271-9.
- [97] Manzano M, et Al. Is  $\beta$ -hydroxy- $\beta$ -methylbutyrate (HMB) the bioactive metabolite of L-leucine (LEU) in muscle? Molecular evidence and potential implications. *Abstract presented at: European Society for Clinical Nutrition and Metabolism 31<sup>st</sup> Congress; Vienna, Austria; August 29-September 1, (2009). Abstract P267.*
- [98] Baxter J et Al. *4th cachexia conference 2007, Abstract 1.18*
- [99] Wilson GJ et Al. Effects of beta-hydroxy-beta-methylbutyrate (HMB) on exercise performance and body composition across varying levels of age, sex, and training experience: A review. *Nutrition & Metabolism* 2008, 5:1 doi:10.1186/1743-7075-5-1
- [100] Peng Xi et Al. Clinical and protein metabolic efficacy of glutamine granules-supplemented enteral nutrition in severely burned patients. *Burns, Vol 31, issue 3* (2005):342-6
- [101] Wilmore DW. The Effect of Glutamine Supplementation in Patients Following Elective Surgery and Accidental Injury. *J Nutr.* (2001);131, Suppl 9:2543S-9S
- [102] Moccheggiani E et Al. Effect of L-arginine on thymic function. Possible role of L-arginine: Nitric oxide (no) pathway. *Archives of Gerontology and Geriatrics. Volume 19, Supplement 1,* (1994): 163-170
- [103] Van del Hulst et Al. Glutamine and the preservation of gut integrity. *Lancet.*, 1993 May 29;341(8857):1363-5.
- [104] Williams JZ. Effect of a Specialized Amino Acid Mixture on Human Collagen Deposition. *Ann Surg.* (2002) September; 236(3): 369-375.
- [105] Curran JN et Al. Biological fate and clinical implications of arginine metabolism in tissue healing. *Wound Repair and Regeneration, Volume 14, Issue 4 July-August* (2006): 376-386, 2006
- [106] Barbul A et Al. Arginine enhances wound healing and lymphocyte immune responses in humans. *Surgery.* (1990) Aug;108(2):331-6
- [107] Witte MB, Barbul A. Arginine physiology and its implication for wound healing. *Wound Repair and Regeneration, Volume 11, Issue 6, November* (2003):419-423,



- [108] Rhodes P et Al. Arginine, lysine and ornithine as vasodilators in the forearm of man. *European Journal of Clinical Investigation, Volume 26, Issue 4, April (1996) pages 325-331*
- [109] Tatti P, Barber AB. Nutritional supplement is associated with a reduction in healing time and improvement of fat-free body mass in patients with diabetic foot ulcers. *EWMA Journal vol 10 no 3(2010): 13-17*
- [110] Tatti P et Al. Effect of a nutritional supplement used for diabetic foot ulcers on microalbuminuria. DOI 10.1007/s12349-011-0072-9



## **Global Perspective on Diabetic Foot Ulcerations**

Edited by Dr. Thanh Dinh

ISBN 978-953-307-727-7

Hard cover, 278 pages

**Publisher** InTech

**Published online** 09, December, 2011

**Published in print edition** December, 2011

Over the last decade, it is becoming increasingly clear that diabetes mellitus is a global epidemic. The influence of diabetes is most readily apparent in its manifestation in foot complications across cultures and continents. In this unique collaboration of global specialists, we examine the explosion of foot disease in locations that must quickly grapple with both mobilizing medical expertise and shaping public policy to best prevent and treat these serious complications. In other areas of the world where diabetic foot complications have unfortunately been all too common, diagnostic testing and advanced treatments have been developed in response. The bulk of this book is devoted to examining the newest developments in basic and clinical research on the diabetic foot. It is hoped that as our understanding of the pathophysiologic process expands, the devastating impact of diabetic foot complications can be minimized on a global scale.

### **How to reference**

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Patrizio Tatti and Annabel Barber (2011). Nutritional Treatment of Diabetic Foot Ulcers - A Key to Success, Global Perspective on Diabetic Foot Ulcerations, Dr. Thanh Dinh (Ed.), ISBN: 978-953-307-727-7, InTech, Available from: <http://www.intechopen.com/books/global-perspective-on-diabetic-foot-ulcerations/nutritional-treatment-of-diabetic-foot-ulcers-a-key-to-success>

**INTECH**  
open science | open minds

### **InTech Europe**

University Campus STeP Ri  
Slavka Krautzeka 83/A  
51000 Rijeka, Croatia  
Phone: +385 (51) 770 447  
Fax: +385 (51) 686 166  
[www.intechopen.com](http://www.intechopen.com)

### **InTech China**

Unit 405, Office Block, Hotel Equatorial Shanghai  
No.65, Yan An Road (West), Shanghai, 200040, China  
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元  
Phone: +86-21-62489820  
Fax: +86-21-62489821

© 2011 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen